Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti CD22 chimeric antigen receptor T cell therapy - Shanghai Unicar-Therapy Bio-medicine Technology

Next Previous
X
Search
Drug Profile

Anti CD22 chimeric antigen receptor T cell therapy - Shanghai Unicar-Therapy Bio-medicine Technology

Alternative Names: CD22-CART - Shanghai Unicar-Therapy Bio-medicine Technology

Latest Information Update: 14 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Unicar-Therapy Bio-medicine Technology
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 12 Oct 2022 Anti CD22 chimeric antigen receptor T cell therapy is still in phase II trials for Non Hodgkin Lymphoma in China (NCT04539444)
  • 11 Dec 2021 Efficacy and adverse events data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2021)
  • 11 Dec 2021 Efficacy and adverse events data from a phase-II trial in Non-Hodgkin's lymphoma presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top